Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

RNN $0.75 0.0407 +5.76%
MEIP $6.97 0.2400 +3.57%
GALT $5.42 0.1400 +2.65%
CYTR $2.82 0.0700 +2.55%
NYMX $4.24 0.0900 +2.17%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

THLD $4.09 -0.3800 -8.50%
ONTX $4.30 -0.3800 -8.12%
CRIS $1.41 -0.1150 -7.57%
SNTA $3.29 -0.2600 -7.32%
CNDO $1.81 -0.1400 -7.18%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

The Newest Precision Medicine Tool: Prostate Cancer Organoids

(Weill Cornell Medical College) Sept 4, 2014 - Research led by investigators at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College has shown for the first time that organ tissue derived from human prostate cancer tumors can be grown in the laboratory, giving researchers a new tool to test cancer drugs and personalize cancer treatment.
read press release 

Is Soy a Foe to Women With Breast Cancer?

(Philadelphia Inquirer/HealthDay News) Sept 5, 2014 - Soy protein may increase activity in genes linked to breast cancer growth -- at least in certain women who already have the disease, a new study suggests.
read article 

Research Finds No Association Between Wearing a Bra and Breast Cancer

(AACR) Sept 5, 2014 - A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
read press release 

New Study: Excellent Outcomes at Five Years With SAVI Breast Brachytherapy Treatment For Early-Stage Breast Cancer

(PRWeb) Sept 4, 2014 - Cianna Medical, Inc., a women’s health company, today announced the release of long-term data supporting the efficacy and safety of breast brachytherapy with the SAVI® applicator.
read press release 

UofL Breast Cancer Researcher Finds Success With Once-Weekly Regimen

(UofL Today/University of Louisville) Sept 4, 2014 - An experimental regimen of once-weekly breast irradiation following lumpectomy provides more convenience to patients at a lower cost, results in better completion rates of prescribed radiation treatment, and produces cosmetic outcomes comparable to the current standard of daily radiation.
read article 

Novel Immunotherapy Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients

(MD Anderson) Sept 5, 2014 - A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence.
read press release 

FDA Approves New Kind of Cancer Drug, Keytruda, For Treating Melanoma

(Washington Post/Associated Press) Sept 4, 2014 - Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug that has big advantages over chemotherapy and other older cancer treatments.
read article (free registration required) 

U.S. Approves Merck Immune-Stimulating Drug For Melanoma

(Reuters) Sept 4, 2014 - U.S. regulators on Thursday approved the use of Merck & Co Inc's immuno-oncology drug Keytruda, also known as pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies.
read article 

Study of Jewish Women Shows Link to Cancer Without Family History

(New York Times) Sept 4, 2014 - Women of Ashkenazi Jewish descent who tested positive for cancer-causing genetic mutations during random screenings have high rates of breast and ovarian cancer even when they have no family history of the disease, researchers reported Thursday.
read article 

Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy

(Merck) Sept 4, 2014 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
read corporate press release 

Roche's Levinson Resigns From Board

(Wall Street Journal) Sept 4, 2014 - Arthur Levinson has quit the board of Swiss pharmaceutical giant Roche Holding AG to focus on leading Google Inc.'s secretive Calico LLC life-sciences company.
read article (paid subscription required) 

Lilly's Diabetes Drug Trumps Sanofi's in Late-Stage Trials

(Reuters) Sept 4, 2014 - Eli Lilly and Co said its diabetes drug was more effective than Sanofi SA's approved drug, Lantus, in reducing blood sugar levels in late-stage trials.
read article 

Google Joins AbbVie in $1.5 Billion Aging Disease Effort

(Bloomberg) Sept 3, 2014 - AbbVie Inc., the drugmaker spun off from Abbott Laboratories last year, and Google Inc.’s Calico will spend as much as $1.5 billion to tackle age-related diseases, including cancer and neurodegenerative disorders.
read article 

Can Big Data and Patient-Informed Consent Coexist?

(Politico) Sept 3, 2014 - A research network funded with millions by the Affordable Care Act will begin conducting vast studies next year to compare standard medical treatments. But what about the 100 million patients in the network — do they have a choice in the matter?
read article 

The End of Health Care’s Historic Spending Slowdown Is Near

(Washington Post/Wonkblog) Sept 3, 2014 - The historic slowdown in health-care spending has been one of the biggest economic stories in recent years — but it looks like that is soon coming to an end.
read article (free registration required) 

He's Having Fun Blasting Away at Lung Cancer With a Five-Foot Rifle

(Bloomberg) Sept 3, 2014 - “Let’s go shoot Savannah,” Tom Galjour says as we bounce along in his vanilla-colored Dodge Ram pickup.
read article 

Oncology Experts Mark 20 Years of Evidence-Based Decision-Making in Small Cell Lung Cancer

(NCCN) Sept 4, 2014 - NCCN has published the 20th annual edition of its NCCN Guidelines® for Small Cell Lung Cancer, marking the first 20th edition of the eight original NCCN Guidelines published in November 1996.
read press release 

Time to Change Primary Care Melanoma Screening Guidelines

(Medscape Medical News) Sept 4, 2014 - Routine targeted screening for melanoma by primary care physicians would be cost-effective but would require better reimbursement and special training to help physicians improve skills for examining pigmented lesion, according to an essay published online September 3 in JAMA Dermatology.
read article (free registration required) 

Colon Capsule Maker Mulls Raising $60 Million in IPO

(Bloomberg) Sept 4, 2014 - Check-Cap, which developed an ingestible capsule designed to detect early signs of colorectal cancer, plans to raise as much as $60 million in an initial public offering, according to a person familiar with the matter.
read article 

CeloNova BioSciences Receives Expanded Indication in Liver Cancer

(MarketWatch) Sept 3, 2014 - CeloNova BioSciences, Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance expanding the indication for their innovative Oncozene® and Embozene® microsphere products to now include the embolization of Hepatoma.
read article 

Ipsen Announces Acceptance of Filings For Somatuline® in the Treatment of GEP-NETs 1 in the US With Priority Review and in Europe

(Ipsen) Sept 1, 2014 - Ipsen today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of its supplemental New Drug Application (sNDA) for Somatuline® Depot® 120mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
read corporate press release 

Highmark Sues UPMC For Cancer Treatment 'Overbilling'

(Pittsburgh Post-Gazette) Sept 4, 2014 - Highmark’s attempt to recover, by way of a lawsuit, hundreds of millions of dollars in chemotherapy-related “markups” paid to UPMC over the past four years could be a “landmark and precedent-setting event,” according to a medical billing expert.
read article 

Cleave Biosciences Initiates Phase 1 Clinical Trial of CB-5083 in Patients with Multiple Myeloma

(San Francisco Business Times) Sept 4, 2014 - Cleave Biosciences today announced that it has begun a Phase 1 clinical trial to evaluate its lead drug candidate, CB-5083, in patients with relapsed and refactory multiple myeloma.
read article 

TRACON Pharmaceuticals Initiates Phase 2 Clinical Trial of TRC105 in Patients With Soft Tissue Sarcoma

(4-traders) Sept 4, 2014 - TRACON Pharmaceuticals today announced the initiation of dosing in the Phase 2 portion of a clinical trial evaluating TRC105 in combination with Votrient (pazopanib), a vascular endothelial growth factor (VEGF) inhibitor, to treat patients with soft tissue sarcoma.
read article 

Melanoma Risk Is Higher For Flight Crews That Work at 40,000 Feet

(Los Angeles Times) Sept 3, 2014 - For both pilots and flight attendants, the risk of developing melanoma was more than double the risk seen in people who worked on the ground according to UC San Francisco researchers.
read article (free registration required)